210 likes | 531 Views
Vendor Update SLA P&HT Division Meeting April 8, 2008. Adis R&D Insight - Statistics. Total number of RDI drug profiles = 23,296 Number of new profiles added per month = 80 Number of significant updates per month = 992 Active drug profiles = 43.1% of the total database.
E N D
Vendor Update SLA P&HT Division Meeting April 8, 2008
Adis R&D Insight - Statistics • Total number of RDI drug profiles = 23,296 • Number of new profiles added per month = 80 • Number of significant updates per month = 992 • Active drug profiles = 43.1% of the total database. • Inactive/discontinued drug profiles = 56.9% of database. • Number of profiles with chemical structures = 8952 • Number of companies covered = 3589 • Number of company profiles linked = 406 • Number of companies tracked by Lehman Bros = 80-100 • Number of profiles with a Lehman table = 995 • Therapeutic Area Coverage = ALL plus Diagnostic agents, Cell therapies, Gene therapies and Vaccines. • Number of Indications = 1283*February 2008
Adis R&D Insight: Sources • Detailed drug profiles derived from the following sources • Company contacts • Press releases • International conferences • Company websites • More than 1,300 biomedical / medical journals
Adis R&D Insight NEW! For 2007/2008 • Upgraded search functionality • Improved ease of use • Links to original sources • Major improvements to customizing preferences and push alerting
Upgraded Search Functionality Biological and Chemical Class • BROWSE function • Separate lists for Biological and Chemical classes • List View/Tree View option • Allows searching on synonyms
Upgraded Search Functionality Route and Formulation • New tab allows search by • Route of administration • Formulation
Upgraded Search Functionality • Organization • Renamed parameter for better classification of drug developers • Search by Organization Type or Ownership Type
Upgraded Search Functionality • Phase • ‘Highest Phase’ and ‘Phase is’ • New ‘Phase filter’ option • Updated and expanded Phase list
Upgraded Search Functionality • Country Hierarchy • Country searching is expanded to provide the ability to confidently and simply search by broad geographical / political region. • Addition of ‘Tree View’
Upgraded Search Functionality • Fast Track • Allows to search compounds that were assigned Fast Track status by the FDA in the US
Upgraded Search Functionality • ‘Orphan Drug’ • Orphan Drug designation for a particular indication • Orphan designation country • ‘Any Indication or Country’: search ALL profiles were Orphan Drug exists
Upgraded Search Functionality • Full Text • ‘Full Text’ has replaced the ‘Text Contains’ free text searching option. • Can be partnered with a Category, which will search a specific part of the profile. • Search term will be highlighted in yellow when you open the profile
Improved Ease of Use • Addition of Disease Qualifiers • a qualifier may be added to an indication • a qualifier comment can be added to provide additional information
Improved Ease of Use • More Tabular Content • Route listed in Phase of Development Table • Orphan Designation • Brand Name Table
Links to Original Sources Journal FullText option in records • Open access linking capability to link to your journal holdings
Customization • Results Page • Choose Columns for viewing on Results Page
Customization • Development table • Filtering by search • Sorting by heading
Alerts • New ALERTS features: • Multiple email addresses can be set up for a single email alert • Searches from both R&D Insight and Clinical Trials Insight can be included in a single alert • Users will be able to export, print, chart results from their Alerts • Run search from last alert
Customer Engagement Activities- 2007 • Online Surveys conducted • Key Takeaways • Areas of expanding importance are drug targets and new formulations • Greater need for financial data, patent, and licensing/deals opportunities • Improved ability in accessing specific data points • Timeliness and comprehensiveness is critical
Next Steps for Adis R&D Insight • Customer roundtables to determine and continue to drive specific major enhancements • US and Europe during the weeks of March 31st and April 4th • Representation from all user and customer types • Improve comprehensiveness of coverage through the content acquisition initiative (technology and process review)
Feedback and Comments Adis Business Intelligence Client Services clientsupport@wolterskluwer.com 1-877-872-2347 option 1